Ventana's c-Kit test for GISTs:
This article was originally published in Clinica
The US FDA has approved for sale Ventana Medical Systems' VentanaDx, a diagnostic kit for allowing physicians to detect c-KIT protein in gastrointestinal stromal tumours (GISTs). While not the sole basis for making a diagnosis of GIST, c-KIT can help in the selection of patients who may be eligible for treatment with Novartis' Gleevec (imatinib mesylate), said Tucson, Arizona-based Ventana. GISTs belong to a rare family of tumours known as soft tissue sarcomas, which most often develop in the stomach, but may also affect the small intestine, colon or oesophagus.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.